Biotech Values

[genisi]

GIVN

From the ''Globes'' piece:

The company hopes to obtain US Food and Drug Administration (FDA) approval by the end of the year. US marketing approval and insurance indemnification will add another $1.7 billion market.

They didn't mention that if approved (and chances seem good), it will be for a fairly narrow indication.